X4 Pharmaceuticals Appoints Michael Wyzga as Chair of Board of Directors

X4
Pharmaceuticals, a clinical-stage biotechnology company developing
novel CXCR4
allosteric antagonist drug candidates designed to improve immune cell
trafficking to treat rare diseases and cancer, today announced the
appointment of Michael Wyzga as the Chair of the company’s Board of
Directors. Mr. Wyzga is an accomplished biopharmaceutical industry
leader with decades of strategic, management and operational experience
at companies at many stages of growth, including companies focused on
rare diseases and cancer.

From 1998 to 2011, Mr. Wyzga held various senior leadership positions at
Genzyme Corporation, a global biotechnology company, including serving
as its Executive Vice President, Finance and Chief Financial Officer.
Between December 2011 and November 2013, Mr. Wyzga served as President
and Chief Executive Officer and a member of the Board of Directors of
Radius Health, a biopharmaceutical company focused on developing new
therapeutics for the treatment of osteoporosis and women’s health
conditions. Currently, Mr. Wyzga is the CEO and President of MSW
Consulting Inc. Additionally, Mr. Wyzga serves on the Board of Directors
for several biopharmaceutical companies, including Akebia Therapeutics,
Inc., Exact Sciences Corporation, and GenSight Biologics. Mr.
Wyzga received a BS from Suffolk University and an MBA from Providence
College.

“Mike Wyzga is a distinguished leader in the biotech community. He
brings the perspectives of his 30 years of industry experience founded
in the delivery life-changing therapies for patients across the world.
Additionally, Mike brings a strong understanding of corporate governance
and management, as well as deep strategic, finance and operational
experience that will support X4 in this rapidly growing stage of the
company,” said Paula Ragan, PhD, President and CEO of X4. “We are very
pleased to have him join X4 Pharmaceuticals as the Chair of our Board of
Directors.”

“X4 is developing novel therapeutics that have shown promising clinical
data in two important therapeutic areas, rare diseases and cancer,” said
Mr. Wyzga. “X4 has made impressive achievements to date with its
pipeline of drug candidates, and I look forward to contributing to the
company’s continued success in developing needed therapies for patients.”

About X4 PharmaceuticalsX4
Pharmaceuticals is developing novel therapeutics designed to improve
immune cell trafficking to treat rare diseases and cancer. The Company’s
oral small molecule drug candidates antagonize the CXCR4 pathway,
which plays a central role in immune surveillance. X4’s most advanced
product candidate is in a Phase 2/3 clinical trial in patients with WHIM
syndrome, a rare genetic, primary immunodeficiency disease and is
currently under investigation in multiple clinical trials in solid
tumors. X4 was founded and is led by a team with deep product
development and commercialization expertise, including several former
members of the Genzyme leadership team, and is located in Cambridge, MA.
For more information, visit www.x4pharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180712005214/en/

Leave a Comment